Long-Acting Injectable Cabotegravir for HIV-1 Prevention in Women

In a trial involving sub-Saharan African women, intramuscular cabotegravir was superior to oral TDF/FTC for preventing HIV-1 infection.

The long-acting antiretroviral cabotegravir (CAB) is safe and effective at preventing HIV-1 infection in cisgender men and transgender women who have sex with men (NEJM JW Infect Dis Sep 2021 and multiple citations); but what about cisgender women? In a phase 3, double-blind, randomized trial in sub-Saharan Africa, investigators assessed the preventive efficacy of injectable CAB versus daily oral tenofovir disoproxil fumarate–emtricitabine (TDF/FTC) in such women. Participants received daily pills for 5 weeks (either CAB plus TDF/FTC placebo or TDF/FTC plus CAB placebo) followed by intramuscular injections every 8 weeks of either CAB or placebo along with oral pills (TDF/FTC or placebo, depending on study group). In all, 3224 women (median …

Reviewing Author

Carlos del Rio, MD

Disclosures

Grant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; NIH/National Institute on Drug Abuse

Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes; Vaccines

Leadership Positions in Professional SocietiesInternational Antiviral Society–USA (Board of Directors); Infectious Diseases Society of America (Past President)

Carlos del Rio, MD

Disclosures

Grant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; NIH/National Institute on Drug Abuse

Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes; Vaccines

Leadership Positions in Professional SocietiesInternational Antiviral Society–USA (Board of Directors); Infectious Diseases Society of America (Past President)

Long-Acting Injectable Cabotegravir for HIV-1 Prevention in Women

Topics

Reviewing Author